Hiroshi Tokuda

This inventor holds 9 USPTO granted patents. Top assignees: Mitsui Toatsu Chemicals, Incorporated, Mitsui Toatsu Kagaki Kabushiki Kaisha, Mitsui Toatsu Kagaku Kabushiki Kaisha. Active years: 1983-1985.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroshi Tokuda. Retrieved from https://idiyas.com/inventor/hiroshi-tokuda-bt4z03vs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9

% Patents Active = 100.0

Average Co-Inventor Count = 6.9

ph-index = 3

Forward Citations = 15(Granted Patents)

Location History:

Chiba, JP (1984)
Mobara, JP (1983 - 1985)

Company Filing History:

6 out of 1,379

Mitsui Toatsu Chemicals, Incorporated

patents

1 out of 1

Mitsui Toatsu Kagaki Kabushiki Kaisha

patent

1 out of 7

Mitsui Toatsu Kagaku Kabushiki Kaisha

patents

4. 1 out of 1

Mitsui Toatsu Kaguku Kabushiki Kaisha

patent

Years Active: 1983-1985

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4532137 - 2-Thiazolamine derivatives, process for preparing same, and (1985-07-30),

2. 4524147 - Uracil derivatives, process for preparing same, and pharmaceutical (1985-06-18),

3. 4511574 - N-(4-Phenyl-2-thiazolyl)carbamate derivatives (1985-04-16),

4. 4501750 - Thiazole compounds, a process for preparing same and a pharmaceutical (1985-02-26),

5. 4490393 - Thiazolylurea derivatives, a process for preparing same and a (1984-12-25),

6. 4476128 - 2-Substituted thiazolyl-piperazine compounds, process for preparation (1984-10-09),

7. 4473577 - 2-Thiazolamine derivatives, process for preparing same, and (1984-09-25),

8. 4446133 - 1-Phenyl-4-carbamoyl piperazine compounds, process for preparation (1984-05-01),

9. 4420481 - Use of piperazine compounds as immunopotentiating agents (1983-12-13),

Title: Hiroshi Tokuda: Innovator in Pharmaceutical Chemistry

Introduction

Hiroshi Tokuda is a notable inventor based in Mobara, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on various chemical compounds. With a total of 9 patents to his name, Tokuda has established himself as a key figure in the development of new pharmaceutical agents.

Latest Patents

Among his latest patents are the 2-Thiazolamine derivatives, which include a process for preparing these compounds. These derivatives are characterized by a general formula where R₁ and R₂ represent lower alkyl radicals with 1 to 4 carbon atoms. Additionally, X can represent various radicals, including lower alkyl, lower alkoxy, and halogenoalkoxy radicals. Tokuda's work also includes the development of pharmaceutical compositions that exhibit immunomodulatory activity, showcasing the potential therapeutic applications of these derivatives. Another significant patent involves Uracil derivatives, further emphasizing his expertise in creating valuable pharmaceutical compounds.

Career Highlights

Hiroshi Tokuda has worked with prominent companies in the chemical industry, including Mitsui Toatsu Chemicals, Incorporated and Mitsui Toatsu Kagaki Kabushiki Kaisha. His experience in these organizations has allowed him to collaborate with other experts in the field and contribute to groundbreaking research and development.

Collaborations

Throughout his career, Tokuda has collaborated with notable coworkers such as Yutaka Okazaki and Isao Sakano. These partnerships have played a crucial role in advancing his research and expanding the impact of his inventions.

Conclusion

Hiroshi Tokuda's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his importance in the field. His work continues to influence the development of new therapeutic agents, making a lasting impact on healthcare.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]